BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25481243)

  • 1. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.
    Visconte V; Tabarroki A; Zhang L; Parker Y; Hasrouni E; Mahfouz R; Isono K; Koseki H; Sekeres MA; Saunthararajah Y; Barnard J; Lindner D; Rogers HJ; Tiu RV
    J Hematol Oncol; 2014 Dec; 7():89. PubMed ID: 25481243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
    Visconte V; Rogers HJ; Singh J; Barnard J; Bupathi M; Traina F; McMahon J; Makishima H; Szpurka H; Jankowska A; Jerez A; Sekeres MA; Saunthararajah Y; Advani AS; Copelan E; Koseki H; Isono K; Padgett RA; Osman S; Koide K; O'Keefe C; Maciejewski JP; Tiu RV
    Blood; 2012 Oct; 120(16):3173-86. PubMed ID: 22826563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gene mutation and myelodysplastic syndromes with ring sideroblast excess].
    Meng FK; Huang LF; Zhou JF; Sun HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1088-90. PubMed ID: 23998618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts.
    Seo JY; Lee KO; Kim SH; Kim K; Jung CW; Jang JH; Kim HJ
    Ann Hematol; 2014 Apr; 93(4):603-8. PubMed ID: 24141330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
    Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
    Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts.
    Conte S; Katayama S; Vesterlund L; Karimi M; Dimitriou M; Jansson M; Mortera-Blanco T; Unneberg P; Papaemmanuil E; Sander B; Skoog T; Campbell P; Walfridsson J; Kere J; Hellström-Lindberg E
    Br J Haematol; 2015 Nov; 171(4):478-90. PubMed ID: 26255870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory anemia with ring sideroblasts.
    Malcovati L; Cazzola M
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):377-85. PubMed ID: 24507814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis with Cooccurrent SF3B1 and MPL Gene Mutations: A Case Report and Brief Review of the Literature.
    Park CH; Yun JW; Kim HY; Lee KO; Kim SH; Kim HJ
    Lab Med; 2020 May; 51(3):315-319. PubMed ID: 31858134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
    Patnaik MM; Tefferi A
    Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.
    Patnaik MM; Lasho TL; Hodnefield JM; Knudson RA; Ketterling RP; Garcia-Manero G; Steensma DP; Pardanani A; Hanson CA; Tefferi A
    Blood; 2012 Jan; 119(2):569-72. PubMed ID: 22096241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].
    Wang JY; Ma J; Lin YN; Wang J; Shen H; Gui FM; Han C; Li QH; Song Z; Wang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):192-197. PubMed ID: 28395441
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts.
    Mupo A; Seiler M; Sathiaseelan V; Pance A; Yang Y; Agrawal AA; Iorio F; Bautista R; Pacharne S; Tzelepis K; Manes N; Wright P; Papaemmanuil E; Kent DG; Campbell PC; Buonamici S; Bolli N; Vassiliou GS
    Leukemia; 2017 Mar; 31(3):720-727. PubMed ID: 27604819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
    Yoshimi A; Abdel-Wahab O
    Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.
    Li P; Shahmarvand N; Lynch D; Gotlib JR; Merker JD; Zehnder JL; George TI; Ohgami RS
    Int J Lab Hematol; 2019 Jun; 41(3):345-352. PubMed ID: 30811101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts.
    Cui R; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Zhang Y; Xiao Z
    Leuk Res; 2012 Nov; 36(11):1428-33. PubMed ID: 22921018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS).
    Ohba R; Furuyama K; Yoshida K; Fujiwara T; Fukuhara N; Onishi Y; Manabe A; Ito E; Ozawa K; Kojima S; Ogawa S; Harigae H
    Ann Hematol; 2013 Jan; 92(1):1-9. PubMed ID: 22983749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
    Broséus J; Alpermann T; Wulfert M; Florensa Brichs L; Jeromin S; Lippert E; Rozman M; Lifermann F; Grossmann V; Haferlach T; Germing U; Luño E; Girodon F; Schnittger S;
    Leukemia; 2013 Sep; 27(9):1826-31. PubMed ID: 23594705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
    Malcovati L; Cazzola M
    Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.
    Visconte V; Makishima H; Jankowska A; Szpurka H; Traina F; Jerez A; O'Keefe C; Rogers HJ; Sekeres MA; Maciejewski JP; Tiu RV
    Leukemia; 2012 Mar; 26(3):542-5. PubMed ID: 21886174
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.